



VIA HAND DELIVERY OCTOBER 15TH, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: Ni et al.

Application Serial No.: 10/041,574

Art Unit: 1646

OCT 22 2003

Filed: January 10, 2002

Examiner: O'Hara, E. TECH CENTER 1600/2900

For: Antibodies to Human Tumor Necrosis
Factor Receptor TR9 (As Amended)

Attorney Docket No.: PF375P1D1

RESPONSE WITH AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed July 15, 2003 (Paper No. 8), please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (a) a Fee Transmittal, with appropriate fee(s); (b) a Terminal Disclaimer under 37 C.F.R. § 1.321(b); (c) a Statement by Attorney for Applicants Regarding Permanence and Availability of Deposited Plasmids; and (d) Legible copies of references BD and BE.

Prior to further examination, Applicants respectfully request entry of the following amendments.

- Amendments to the Specification begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.
- Remarks begin on page 14 of this paper.